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Abstract
Background: Undiagnosed and misdiagnosed tuberculosis (TB) drives the epidemic in India. Serological (antibody
detection) TB tests are not recommended by any agency, but widely used in many countries, including the Indian private
sector. The cost and impact of using serology compared with other diagnostic techniques is unknown.
Methods and Findings: Taking a patient cohort conservatively equal to the annual number of serological tests done in India
(1.5 million adults suspected of having active TB), we used decision analysis to estimate costs and effectiveness of sputum
smear microscopy (US$3.62 for two smears), microscopy plus automated liquid culture (mycobacterium growth indicator
tube [MGIT], US$20/test), and serological testing (anda-tb ELISA, US$20/test). Data on test accuracy and costs were obtained
from published literature. We adopted the perspective of the Indian TB control sector and an analysis frame of 1 year. Our
primary outcome was the incremental cost per disability-adjusted life year (DALY) averted. We performed one-way
sensitivity analysis on all model parameters, with multiway sensitivity analysis on variables to which the model was most
sensitive. If used instead of sputum microscopy, serology generated an estimated 14,000 more TB diagnoses, but also
121,000 more false-positive diagnoses, 102,000 fewer DALYs averted, and 32,000 more secondary TB cases than microscopy,
at approximately four times the incremental cost (US$47.5 million versus US$11.9 million). When added to high-quality
sputum smears, MGIT culture was estimated to avert 130,000 incremental DALYs at an incremental cost of US$213 per DALY
averted. Serology was dominated by (i.e., more costly and less effective than) MGIT culture and remained less economically
favorable than sputum smear or TB culture in one-way and multiway sensitivity analyses.
Conclusions: In India, sputum smear microscopy remains the most cost-effective diagnostic test available for active TB;
efforts to increase access to quality-assured microscopy should take priority. In areas where high-quality microscopy exists
and resources are sufficient, MGIT culture is more cost-effective than serology as an additional diagnostic test for TB. These
data informed a recently published World Health Organization policy statement against serological tests.
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Improved diagnostic testing represents a key component of
tuberculosis (TB) control [1–3], and inadequate case detection is a
major hurdle for effective control of the TB epidemic. Sputum
smear microscopy, the current backbone of TB diagnosis
worldwide, misses 50% of all cases and is often performed under
suboptimal laboratory conditions [4–6]. Thus, if targets for TB
control are to be achieved, newer diagnostic tools for active TB
must be used. On the basis of available evidence [7,8], the World
Health Organization (WHO) currently recommends several
technologies for TB diagnosis [9], including culture of Mycobac-
terium tuberculosis using commercial liquid media (e.g., mycobacteria
growth indicator tube [MGIT], BD Diagnostics) or noncommer-
cial methods (e.g., microscopic observation drug susceptibility
[MODS]), and more recently, rapid molecular testing with the
Xpert MTB/RIF system (Cepheid, Inc.) [10,11]. However, TB
culture often takes weeks to obtain results, and all currently
recommended diagnostic tests (other than microscopy) require
infrastructure currently unavailable in many settings [7,8,12].
Although promising, technologies such as MODS and Xpert
MTB/RIF are yet to be scaled up in India. Before investing in
additional infrastructure, it is important to assess whether other,
more immediately accessible, TB diagnostic tests might be cost-
effective.
Serological tests for active TB are based on detection of
antibodies elicited by antigens of Mycobacterium tuberculosis that are
recognized by the humoral immune system. Many serological tests
utilize an ELISA format, while several others are available as rapid
point-of-care tests (e.g. immunochromatographic, lateral flow
assays). Thus, serological tests are attractive because they are
faster and simpler to perform than most sputum-based methods
[13]. However, as demonstrated in a recent updated systematic
review [14], existing evidence supporting commercial serological
tests is inconsistent and of low quality. Although no international
guideline recommends their use, serological tests for active TB are
readily available and widely used in parts of the developing world,
including India and at least 16 of 21 other high-burden countries
[15]. Thus, while unlikely to be as accurate as TB culture,
serological tests might still be preferred over sputum smear
microscopy, and serology might also be economically attractive
relative to culture and molecular tests given fewer infrastructure
requirements, faster turnaround time, and higher volume of usage.
The economic implications of serological testing for TB are
substantial. In India, at least 13 different TB serological kits are on
the market (Table 1), and an estimated 1.5 million serological tests
for active TB are performed every year (primarily in the private
medical sector), at a cost of over US$15 million for testing alone
[15,16]. To better understand the economic and epidemiological
consequences of serological testing for active TB in India, we
analyzed costs and effectiveness from the perspective of the
combined public and private TB control sector of the health care
system.
Methods
We constructed a decision-analytic model to estimate the costs
and effectiveness of serological testing for active TB. The basic
model structure (Figure 1) was adapted from a previously
described cost-effectiveness analysis of novel TB diagnostics [17].
This static model evaluates outcomes (including secondary TB
transmission) in a cohort of TB suspects. We took as our study
population a hypothetical cohort of 1.5 million adult TB suspects
in India, presenting for diagnosis in settings with access to
serological testing. Thus, this cohort provides a conservative
estimate of costs and outcomes among all Indian patients receiving
serological testing for active TB in a given year. These patients
were assumed to have TB prevalence, HIV prevalence, and access
to antiretroviral therapy representative of adults with suspected TB
in India as a whole [18,19].
To evaluate various diagnostic strategies, we conducted a two-
stage analysis. In the first stage, we sought to identify the best
initial test for TB. In the second stage, we sought to evaluate the
optimal diagnostic strategy for improved TB diagnosis in settings
Table 1. Serological assays for tuberculosis on the Indian market.
Company Kit Assay Technique
Sensitivity and Specificity
from Package Insert URL
Anda Biologicals, Strasbourg, France anda TB-ELISA ELISA Not listed, refers to publications http://www.andabiologicals.com
Omega Diagnostics, Alva, Scotland Pathozyme TB Complex Plus ELISA 37% and 100% http://www.omegadiagnostics.com
Tulip Group, Goa Qualisa TB ELISA 100% and 99% http://www.tulipgroup.com
Tulip Group, Goa Serocheck-MTB Rapid
a 100% and 100% http://www.tulipgroup.com
Span Diagnostics, Surat TB Spot Ver 2.0 Rapid
a 80% and 99% http://www.span.co.in
Bhat Biotech, Bangalore Bhat Bioscan TB card Rapid
a 83% and 99% http://www.bhatbiotech.com/
Span Diagnostics, Surat Mycowell ELISA ‘‘Superior sensitivity and
specificity’’
http://www.span.co.in
J Mitra, New Delhi TB IgG, IgM, IgA Elisa ELISA 80% and 97% http://www.jmitra.co.in
JB Trop Dis Res Centre, Sevagram SEVA TB ELISA ELISA 97% and 99% http://www.jbtdrc.org/SEVA_TB.pdf
S.D. Bio Standard Diagnostic India SD BIOLINE Rapid TB Rapid
a 98% and 99% http://sdbiostandard.tradeindia.
com/
Bisen Biotech, Gwalior TB SCREEN TEST Rapid
a 94% and 98% http://www.bisenbiotechindia.com
Lab-care Diagnostics Pvt Ltd, Sarigam Accucare Rapid TB test Rapid
a .80% sensitivity and specificity http://www.labcarediagnostics.com/
RapidTest_sub.html
Tashima Inc, Bangalore TB IgG/IgM 3 Line Rapid test Rapid
a 93% and 100% http://www.tashima.net
aRapid chromatographic immunoassay.
doi:10.1371/journal.pmed.1001074.t001
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baseline scenario for the first analysis assumed that the study
population receives the combination of tests (e.g., chest X-ray
[CXR]) and clinical strategies (e.g., antibiotic trials) that is typical
in India, with the exception of using no TB-specific microbiolog-
ical test (including sputum smear microscopy, culture, or serology).
We assumed that the country-wide smear-negative TB case
detection rate in India approximates the ability of clinicians to
successfully diagnose TB in this situation. To evaluate the most
appropriate initial test for TB in this situation, we modeled the
addition to the baseline scenario of sputum smear microscopy
versus serological testing using anda-tb ELISA (Anda Biologicals;
the most widely studied and used serological test in India) [14]. In
the second analytic stage, we assumed that sputum smear
microscopy was performed as an initial test, followed by either
anda-tb ELISA or automated liquid culture on smear-negative
specimens. Our primary outcome for all analyses was the
incremental cost-effectiveness ratio (ICER) relative to the
reference scenario for each analytic stage.
Serology is primarily available in India through stand-alone and
large network (chain) private laboratories which also offer TB
cultures. Thus, we assumed that the population had existing access
to serology (at market prices), and that similar access to TB culture
could be established by constructing an appropriate laboratory
facility; there are currently 27 reference laboratories capable of
culture and drug-susceptibility testing, accredited by the Indian
Revised National TB Control Programme (RNTCP). We assumed
that sputum smear and serology could be performed by send-out
testing to a public or private laboratory with a 1-wk turnaround
time, and that TB culture would incur additional delays of 8 wk
for specimen incubation, reporting of results, and initiation of
treatment [20]. These assumptions were tested in sensitivity
analyses.
Regarding costs, we conservatively estimated that anda-TB
would cost US$20 per person with suspected active TB on the
basis of data from private labs in India [15,16], although the total
cost per patient often exceeds US$40 (because three antibodies—
IgA, IgG, and IgM—are often requested). We assumed that the
cost per TB culture was US$20, approximately equal to the cost of
automated MGIT culture, including the costs of laboratory
construction and overheads, when run at half-maximum through-
put in Zambia [21]. Patients diagnosed with TB were assumed to
be treated according to RNTCP national standards.
Accuracy for each test was estimated from published literature,
including meta-analyses where available [14,22,23]. For TB
serology, we used the sensitivity and specificity of anda-TB, the
most widely studied test according to a recently updated meta-
analysis [14]. Since anda-TB is likely to outperform more poorly
studied in-house serological tests and less accurate rapid test
formats [14], and laboratory accuracy is likely to exceed that in the
field, our analysis likely overestimates the accuracy of serology as
actually performed in practice. A full listing of estimated
parameter values is given in Table 2.
We assumed that all incremental costs and effects of TB
treatment occur during the first year after presentation with
symptoms of active TB (i.e., that any patient who would be
successfully diagnosed with TB would be diagnosed within 1 y of
presentation). Patients with active TB at the end of this year are
assumed to remain infectious for an additional year [24],
acknowledging that the period of infectivity depends on numerous
variables including HIV status, age, gender, and type (e.g.,
cavitary nature) of disease. Outcomes (e.g., death) occurring within
that year are discounted over the cohort’s lifetime, which was the
analytic time horizon. We lack reliable data on the costs of
hospitalization for TB, lost wages due to TB, or treatment for
other related conditions (e.g., bacterial pneumonia). Thus, we
adopted the perspective of the Indian TB control sector, including
both the public RNTCP and those elements of the private health
care sector devoted to diagnosis and treatment of TB. Our
primary outcome was the incremental cost per disability-adjusted
life year (DALY) averted. All costs were converted to US dollars
using historical exchange rates and inflated to the year 2010 using
the medical care component of the US Consumer Price Index
[25]. We discounted all future costs and effects (DALYs and
secondary TB transmissions) by 3% per year, with sensitivity
analysis for 0% and 7%.
One-way sensitivity analysis was performed on all parameters
across ranges shown in Table 2, with further two-way sensitivity
analysis on those variables to which the model was most sensitive.
In the absence of data to suggest a reasonable parameter range, we
varied each parameter over +/225% of its baseline value. Since
published estimates of serological test accuracy likely overestimate
their actual accuracy in the field, we also evaluated an alternative
scenario using the lower bounds of sensitivity and specificity for
serological testing from a recent meta-analysis [14]. Analyses were
performed using TreeAge Pro 2009 (TreeAge Software, Inc.).
Results
The hypothetical study population of 1.5 million adults with
suspected active TB included an estimated 214,000 cases of active
TB, or 16% of India’s annual burden of incident TB [26]. We
estimated that, in the absence of TB-specific microbiological
testing (i.e., in the baseline scenario), clinicians would diagnose
114,000 (53%) of these patients with TB on the basis of clinical
judgment and nonmicrobiological tests (e.g., chest X-ray [CXR],
antibiotic therapeutic trials) alone. Addition of sputum smear
microscopy to this scenario of no TB-specific testing resulted in
diagnosis of an estimated 44,000 more cases of TB, or 44% of
remaining undiagnosed cases (Table 3). Replacing sputum smear
with serological testing resulted in an estimated 14,000 more
diagnosed cases of TB than did sputum smear, but also resulted in
121,000 additional false-positive diagnoses relative to microscopy.
Because the cases detected by sputum smear are assumed to be
more infectious than those detected by serology, smear was
estimated to avert 102,000 more DALYs and 32,000 more
secondary cases than did serology, at approximately one-fourth the
incremental cost. If performed only on smear-negative specimens,
TB culture was both cheaper and more effective (i.e., dominant)
compared with serological testing (Table 3). For each additional
smear-negative TB case diagnosed by serology, more than six
additional false positives were inappropriately diagnosed.
When we conducted one-way sensitivity analysis of all variables
across the ranges specified in Table 2, no scenario was identified in
which serology was either less costly or more effective than sputum
smear microscopy alone, nor serology plus sputum smear more
cost-effective than MGIT culture plus sputum smear. Reducing
the time to culture-based diagnosis from 8 wk (with 25% loss to
follow-up) to 2 wk (with 15% loss to follow-up, similar to serology)
reduced the incremental cost-effectiveness of culture plus smear,
relative to smear alone, from US$213 to US$188.
The incremental cost-effectiveness of serology was most sensitive
to the sensitivity and specificity of the serological test. By contrast,
the influence of specificity on the cost-effectiveness of sputum
smear was small (incremental cost per DALY averted of US$19
versus US$14 for sputum smear specificity of 97% versus 100%).
Thus, comparing serology alone to sputum smear, we performed
two-way sensitivity analysis around sensitivity and specificity of
Cost-Effectiveness of TB Serology in India
PLoS Medicine | www.plosmedicine.org 3 August 2011 | Volume 8 | Issue 8 | e1001074Figure 1. Study decision tree. Depicted is a simplified version of the analytic framework for this decision analysis. The square represents a decision
node, circles chance nodes, and triangles terminal nodes. The branch of the decision node (sputum smear + serology) is compared to similar branches
corresponding to scenarios of no TB-specific diagnosis, sputum smear only, and sputum smear plus TB culture (commercial liquid media), as
described in the text. Probabilities, costs, and DALYs are calculated at each terminal node according to the parameters described in Table 2. ARV,
antiretroviral therapy; +, positive; 2, negative.
doi:10.1371/journal.pmed.1001074.g001
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Parameter Base Value
Range for Sensitivity
Analysis Reference
TB dynamics
a
Probability of death, untreated smear-positive TB 0.70 0.5–0.95 [4]
Probability of death, untreated smear-negative TB 0.20 0.15–0.25 [4]
Secondary TB infections per year, smear-positive TB 10 8–12 [24]
Relative infectiousness of smear-negative TB 0.22 0.16–0.28 [37]
Fraction of new TB cases that are smear-positive 0.53 0.4–0.66 [4]
Characteristics of TB diagnosis
Prevalence of active TB among persons with suspected active TB 0.14 0.11–0.18 [19]
Sensitivity of clinician diagnosis
b 0.53 0.40–0.67 [26]
Sensitivity for smear-positive TB, serology (anda-TB) 0.76 0.63–0.87 [14]
Sensitivity for smear-negative TB
MGIT TB culture (single specimen) 0.73 0.55–0.91 [23]
Serology 0.59 0.40–0.85 [14]
Specificity for active TB
Clinician diagnosis
b 0.94 0.75–1.0 [3]
Sputum smear microscopy (two smears) 0.97 0.9–1.0 [6]
MGIT TB culture 0.99 0.95–1.0 [23]
Serology 0.87 0.74–0.98 [14]
c
Time to TB diagnosis
MGIT TB culture 8 wk 1–4 mo [20]
Sputum smear, serology 1 wk 3–14 d [38,39]
Loss to follow-up
MGIT TB culture 0.25 0.19–0.31 Estimated
Sputum smear, serology 0.15 0.11–0.19 [40,41]
Characteristics of TB treatment
Proportion of treated TB patients who die 0.045 0.033–0.056 [26]
Proportion of treated HIV/TB patients who die 0.090 0.068–0.114 [26]
Proportion of treated TB patients infectious at 1 y 0.045 0.033–0.056 [26]
HIV/TB
HIV prevalence, general population 0.3% 0.225%–0.4% [18]
HIV prevalence, patients with TB 5.3% 4.0%–6.6% [26]
Proportion of HIV-infected patients with ART access 0.10 0.075–0.125 [18]
Costs and effectiveness, US$
Unit cost, independent laboratory
Sputum smear microscopy (two smears) US$3.62 US$1–US$5 [19]
TB culture (MGIT) US$20 US$10–US$30 [21]
Serology US$20 US$10–US$30 [19]
Mean cost of treating one case of TB US$82.40 US$60–US$100 [26]
DALY weights
a
Active TB 0.264 0.198–0.330 [42]
TB treatment 0.132 0.099–0.165 Estimated
Life expectancy after TB cure (y) 40 30–50 [43,44]
aParameter values for HIV-positive patients are excluded from this table owing to low HIV prevalence but were incorporated into the model and can be found in
reference [17].
bIn the absence of any TB-specific microbiological test.
cExcludes studies not performed in developing countries.
ART, antiretroviral therapy.
doi:10.1371/journal.pmed.1001074.t002
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rating the price of serology and proportion of TB cases presenting
with smear-positive TB. For serological testing to achieve
equivalent effectiveness (in terms of DALYs averted) to sputum
smear microscopy, sensitivity for both smear-positive and smear-
negative TB would be required to exceed 81%–86%, depending
on specificity (Figure 2A). These thresholds are less stringent in
settings where a lower proportion of TB patients present with
smear-positive disease (Figure 2B). Because of the excess cost of
treating false positives, serology (with any sensitivity) would need to
achieve a specificity of .0.92 before a test, even with a price of
US$0.01, could be less costly to the TB control sector than sputum
smear. When we evaluated the lower bounds of published values
for the specificity (0.74) and smear-positive sensitivity (0.63) of
serological testing to compensate for possible publication bias,
serology was estimated to avert 171,000 fewer DALYs and cost
US$48.1 million more than sputum smear microscopy alone.
When added to sputum smear microscopy, serology would need to
achieve exceptional sensitivity and specificity (e.g., 70% sensitivity
and 97% specificity for smear-negative TB) to achieve more
favorable cost-effectiveness ratios than TB culture (Figure 3).
Discussion
This study, in a hypothetical cohort of 1.5 million adult Indian
persons with suspected active TB, suggests that sputum smear
microscopy remains the most cost-effective initial diagnostic test
for active TB, across a wide range of plausible parameter
estimates. In areas where quality-assured microscopy is already
available and resources are sufficient, liquid TB culture is a more
cost-effective addition than serology. As an addition to sputum
smear plus clinical judgment, serology detects more than six false
positives for every new smear-negative TB case appropriately
diagnosed, and from the economic perspective of the Indian TB
control sector, is less favorable than (i.e., dominated by) other
diagnostic options.
This study highlights the substantial adverse economic conse-
quences of serological TB testing in India. Although most
serological testing in India is performed in the private sector,
patients diagnosed with TB (including false positives) are often sent
for treatment in public facilities [27]. The scale-up of the RNTCP
is estimated to have added over US$88 billion in economic benefit
to India over the last 10 y through country-wide implementation
of directly observed therapy, short-course (DOTS) services,
including sputum smear microscopy [28]. Given the scale of the
RNTCP’s activities and its limited budget, any diagnostic strategy
demanding additional resources may divert those resources from
further improvement of sputum smear microscopy or engagement
of the private sector to provide broader access to microscopy or
other new WHO-endorsed diagnostics. If serology is used as a
replacement for sputum smear microscopy in one-third of the
estimated 1.5 million patients receiving serologic TB diagnosis
annually in India [16], we estimate that the Indian TB control
sector would lose an estimated US$11.9 million (approximately
one-sixth the annual budget of the RNTCP) [16], generate 11,000
additional secondary cases of TB (nearly 1% of all incident TB
cases in India) [26], treat 40,000 false-positive patients unneces-
sarily, and cause 34,000 DALYs.
Although we designed this analysis primarily as an evaluation of
serological testing, our secondary results regarding TB culture
suggest that, from the perspective of the Indian TB control sector,
MGIT would be cost-effective, assuming that systems could be put
in place to translate culture results consistently into treatment
decisions [20]. While there is no universal standard for cost-
effectiveness of interventions, those whose cost per DALY averted
is less than a country’s per-capita gross domestic product (GDP,
US$3,100 in India [29]) are considered by the Commission for
Macroeconomics and Health and WHO to be ‘‘very cost-
effective’’ [30]. Sputum smear microscopy is estimated to cost
US$19 per DALY averted, and addition of TB culture to sputum
smear US$213 per DALY averted, speaking to the importance of
efforts to increase India’s TB control budget and to deploy TB
diagnostics in settings where current diagnostic standards are poor
[17]. Indeed, the RNTCP will require substantially higher
resources to scale-up improved and new TB diagnostics in India,
as it begins a new phase (2012–2017).
One important, and often overlooked, consideration in cost-
effectiveness analyses of TB diagnostics is the role of false-positive
results [31]. Most prior cost-effectiveness analyses of TB
diagnostics (e.g., [3,17]) have focused on the importance of high
sensitivity in controlling the TB epidemic, assessing small costs
(e.g., the cost of first-line TB drugs) to patients incorrectly
diagnosed with TB. However, in a setting where a diagnostic test
could result in over six times as many incremental false-positive as
true-positive diagnoses (Table 3), other considerations including
loss of faith in the health care system, ethical concerns of
physicians, and adverse effects of TB therapy may be increasingly
relevant. Furthermore, we assumed a setting where one in seven
Table 3. Cost-effectiveness of diagnostic strategies for 1.5 million persons with suspected active TB in India.
Diagnostic Test Cost (US$)
Additional TB
Cases Treated
Additional
False-Positive
Cases Treated
Secondary
Cases Averted
DALYs
Averted
Incremental
DALYs Averted
Incremental
Cost per DALY
Averted (US$)
Performed alone, relative
to no microbiological
testing
Sputum smear microscopy 11.9 million 44,000 36,000 443,000 623,000 623,000 19
anda-TB serology 47.5 million 58,000 157,000 411,000 520,000 (Dominated) (Dominated)
Performed on smear-
negative specimens only,
relative to sputum smear
alone
MGIT culture 27.6 million 26,000 12,000 112,000 130,000 130,000 213
anda-TB serology 39.0 million 24,000 152,000 112,000 110,000 (Dominated) (Dominated)
doi:10.1371/journal.pmed.1001074.t003
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PLoS Medicine | www.plosmedicine.org 6 August 2011 | Volume 8 | Issue 8 | e1001074Figure 2. Three-way sensitivity analysis: sensitivity and specificity of serology for active TB. Specificity and sensitivity (for smear-positive
and smear-negative TB) would be required to achieve values above the primary line for serology to be more effective than sputum smear microscopy
alone. The vertical and horizontal lines denote the 95% credible intervals of estimated accuracy from published studies of anda-TB [14], the most
widely used serological test in India. (A) compares serology alone against sputum smear microscopy alone in a setting where 53% of TB patients are
smear-positive (base case scenario), while (B) considers a scenario in which only 40% of TB patients are smear-positive.
Figure 3. Two-way sensitivity analysis: serology versus culture for diagnosis of drug-sensitive TB. For the incremental cost-effectiveness
ratio (ICER) to be more favorable for serology than for TB culture using commercial liquid media (MGIT) in the base-case scenario (73% sensitivity and
99% specificity), the sensitivity and specificity of serology for smear-negative TB must achieve values above the primary line. The estimated sensitivity
and specificity of serology in the base case are 59% and 87%, respectively [14].
doi:10.1371/journal.pmed.1001074.g003
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lower, low-specificity diagnostics will perform even more poorly.
Thus, our analysis may be biased against those diagnostics (i.e.,
smear and TB culture) with highest specificity.
A key limitation to this study is its reliance on published data for
parameter estimates, many of which are subject to substantial
variability, as well as the lack of direct data on the full costs
(including purchase of equipment, laboratory scale-up, and
training of staff) of culture. Nevertheless, we were unable to
generate a model in which serology was more effective than
sputum smear or more cost-effective than TB culture despite
variation of each individual parameter by at least 25% of its
baseline value. More importantly, published data on the sensitivity
and specificity of serological testing are limited. For example, a
total of 686 patients (105 from developing countries) have been
reported in the published literature for anda-TB: the most widely
studied serological test, available since 1990 [14]. This number
compares with 1,730 patients reported in the first publication of
Xpert MTB/RIF, a novel molecular test for TB [10], and over
14,000 specimens evaluated by MGIT [23]. Since published
estimates likely overestimate the true performance of novel
diagnostic tests, and in-house ELISA and rapid tests perform
worse than commercial ELISA-based assays [14,32], our analysis
based on published estimates of a commercial ELISA may
overestimate the effectiveness and cost-effectiveness of serology
as implemented in actual practice.
We also acknowledge other limitations to our approach. First,
we were unable to adopt a societal perspective, owing to the lack of
reliable data on the societal costs of TB diagnosis and treatment in
India. Thus, while internally consistent, our analysis should not be
used to compare the cost-effectiveness of improved TB diagnostics
to interventions in other areas of the health care sector. Our
estimate of the cost-effectiveness of sputum smear microscopy plus
TB treatment (US$19 per DALY averted) is nonetheless similar to
that of the World Bank (US$7–US$11 in 2010 dollars for a low-
income country) [33]. Second, since our primary focus was on
serology, we limited our analysis to drug-sensitive TB and did not
conduct a full costing study for culture. Third, we assume a
population (urban and peri-urban) with access to a laboratory
capable of performing serology. This population is not represen-
tative of the entire Indian population, and results from our model
thus should not be generalized to all Indian persons with suspected
active TB. Furthermore, the cost of establishing such laboratory
services may not be entirely reflected in the market prices for these
tests; thus, our model may underestimate the cost of diagnostic
testing in areas where laboratory infrastructure is not preexisting.
Finally, although we estimated secondary transmissions from our
primary cohort, our model has a static 1-y analysis frame and does
not account for changes over time including repeated rounds of
TB transmission. We may therefore underestimate the long-term
cost-effectiveness of improved TB diagnosis [34].
These data were presented to a WHO Expert Group that met in
July 2010 to review the evidence on TB serological assays. This
Expert Group considered the updated meta-analysis on commer-
cial serological tests [14], as well as data from the present analysis
demonstrating that serology is not cost-effective. Based on the
Expert Group’s recommendation, in July 2011, the WHO
published a policy statement on commercial serodiagnostic tests
for diagnosis of TB. The policy states that Commercial serological
tests provide inconsistent and imprecise estimates of sensitivity and
specificity. There is no evidence that existing commercial
serological assays improve patient-important outcomes, and high
proportions of false-positive and false-negative results adversely
impact patient safety. Overall data quality was graded as very low,
with harms/risks far outweighing any potential benefits (strong
recommendation). It is therefore recommended that these tests
should not be used in individuals suspected of active pulmonary or
extra-pulmonary TB, irrespective of their HIV status. The WHO
policy strongly encourages targeted further research to identify
new/alternative point-ofcare tests for TB diagnosis and/or
serological tests with improved accuracy [34,35,45].
In conclusion, this cost-effectiveness analysis suggests that, as an
initial test for active TB among adults in India, serology results in
more DALYs, secondary infections, and false-positive diagnoses
than sputum smear microscopy, while increasing per-patient costs
to the Indian TB control sector. In areas where high-quality
sputum microscopy is available, adding automated liquid culture is
more effective and less costly than adding serology. These data
have been considered by the WHO in recommending against
serological testing for active TB, and will need to be considered by
Indian regulatory and governmental agencies that need to
implement the WHO recommendations.
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Background. Every year, about 2 million people develop
tuberculosis in India—a fifth of the global incidence of
this highly contagious bacterial infection. Mycobacterium
tuberculosis, the bacterium that causes tuberculosis, is spread
in airborne droplets when people with the disease cough or
sneeze and usually infects the lungs although it can also
infect other organs. The characteristic symptoms of
tuberculosis are a persistent cough, weight loss, and night
sweats. Diagnostic tests for tuberculosis include sputum
smear microscopy (microscopic analysis of mucus brought
up from the lungs by coughing), culture (growth) of M.
tuberculosis from sputum samples in liquid media (using, for
example, a commercial product called the mycobacteria
growth indicator tube or MGIT), and nucleic acid amplifi-
cation tests (which detect the bacterium’s genome in patient
samples) such as the Xpert MTB/RIF system. Tuberculosis can
usually be cured by taking several powerful antibiotics daily
for at least 6 months.
Why Was This Study Done? In India, as elsewhere,
undiagnosed and misdiagnosed tuberculosis drives the
tuberculosis epidemic by increasing the transmission of M.
tuberculosis. Unfortunately, sputum smear microscopy, the
current mainstay of tuberculosis diagnosis worldwide, detects
only half of tuberculosis cases, mycobacterial culture can take
weeks to provide a diagnosis, and rapid techniques such as
nucleic acid amplification require infrastructure that is often
not available in developing countries. Consequently, in India
and other developing countries, serological tests are widely
used for the diagnosis of tuberculosis. Serological tests detect
antibodies against M. tuberculosis in the blood (antibodies are
proteins made by the immune system in response to
infections). Serological tests are fast and simple to perform,
but they are not recommended for clinical use, and the
available evidence suggests that they do not diagnose
tuberculosis accurately. Even so, and in the absence of
information about the cost and impact (cost-effectiveness) of
serological testing, about 1.5 million serological tests for
tuberculosis are conducted every year in India at a cost of
more than US$15 million. Here, the researchers analyze the
cost-effectiveness of serological tests compared to other
diagnostic tests from the perspective of tuberculosis control
in India.
What Did the Researchers Do and Find? The researchers
used ‘‘decision analysis’’ to estimate the cost-effectiveness of
sputum smear microscopy, microscopy plus liquid culture
using the MGIT system, and serological testing using the
widely used anda-tb ELISA commercial test in a hypothetical
group of 1.5 million people suspected of having tuberculosis.
Decision analysis formally assesses the decision-making
process by using models that evaluate outcomes under
different scenarios. By feeding data on the costs and
accuracy of different diagnostic tests into their decision-
analysis model, the researchers estimate that, over a
year, serology would generate 14,000 more tuberculosis
diagnoses than sputum microscopy. However, it would also
generate 121,000 more false-positive diagnoses and 32,000
more tuberculosis transmissions to other people (secondary
transmissions), and avert 102,000 fewer disability-adjusted
life years (DALYs; a DALY is a year of healthy life lost because
of premature death or disability) at four times the
incremental cost of sputum microscopy. MGIT culture
added to sputum smear microscopy would avert 130,000
DALYs at an incremental cost of US$213 per DALY averted.
Finally, sensitivity analyses (reruns of the decision-analysis
model using different values for test costs and accuracy)
identified no scenario in which serology was either less costly
or more effective than sputum smear microscopy alone or in
which serology plus sputum microscopy was more cost-
effective than MGIT culture plus sputum microscopy.
What Do These Findings Mean? These findings identify
sputum smear microscopy as the most cost-effective existing
diagnostic test for tuberculosis in India. Moreover, they
suggest that in areas where high-quality microscopy is
available, resources are sufficient, and infrastructure to
effectively use culture exists, the addition of MGIT culture
to sputum smear microscopy would be more cost-effective
than the addition of serology. Importantly, these findings
suggest that, if used as an initial test for tuberculosis in India,
serology would result in more DALYs, more secondary
infections, and more false-positive diagnoses than sputum
smear microscopy while increasing per-patient costs to the
Indian tuberculosis control sector. Given these findings and
the results of a recent updated systematic review on the
accuracy of serological tests, the World Health Organization’s
Strategic and Technical Advisory Group for Tuberculosis
recently advised against the use of currently available
serological tests for the diagnosis of tuberculosis. The WHO
negative policy against serological tests must now be
implemented in India.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001074.
N Details of the recent systematic review of serological tests
for tuberculosis diagnosis are available in a PLoS Medicine
Research Article by Steingart et al.
N The World Health Organization provides information on all
aspects of tuberculosis, including tuberculosis diagnostics
and the Stop TB Partnership (some information is in several
languages); its Strategic and Technical Advisory Group for
Tuberculosis recommendations on tuberculosis diagnosis
are available
N The Evidence-based TB Diagnosis Web site by the Stop TB
Partnership’s New Diagnostics Working Group provides
evidence syntheses on various TB tests, along with
guidelines, resources, and training materials
N The US Centers for Disease Control and Prevention has
information about tuberculosis, including information on
the diagnosis of tuberculosis disease
N The US National Institute of Allergy and Infectious Diseases
also has information on all aspects of tuberculosis
N MedlinePlus has links to further information about
tuberculosis (in English and Spanish)
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